SOLENO THERAPEUTICS, INC.

SOLENO THERAPEUTICS, INC. representing SOLENO THERAPEUTICS, INC. · Q1 2026 · $80,000 · view on lda.senate.gov ↗

Issues lobbied

PHAPharmacy
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
TRDTrade (domestic/foreign)
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
FINFinancial Institutions/Investments/Securities
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
HCRHealth Issues
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
MMMMedicare/Medicaid
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
INSInsurance
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption
ECNEconomics/Economic Development
H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption

Filing UUID: fd446b1b-bea8-487e-a560-e44276f204d8
Filing type: Q1
Filing period: first_quarter
Filing year: 2026
Posted: 2026-05-08T19:42:18-04:00
Registrant (lobbyist): SOLENO THERAPEUTICS, INC.
Client: SOLENO THERAPEUTICS, INC.
Client location: CA / US
Client description: Soleno is focused on development of novel therapeutics for treatment of rare diseases.
Income reported: —
Expenses reported: $80,000